Cas No.: | 185243-69-0 |
pH value: | Corresponds to reference standard: PASS |
Non-reduced CE-SDS: | 98.4% |
SEC-HPLC: | 99.1% |
Isoelectric Point: | Corresponds to reference standard |
Bacterial Endotoxins Test: | <1 EU/ml |
Exogenous Residual DNA: | <1 pg/mg |
Residual protein A: | <1 ng/mg |
Biological Activity: | Compared with standard, the range ofbiological activity is 111% |
Osmolality: | Corresponds to reference standard: PASS |
Peptide mapping: | Corresponds to reference standard: PASS |
N-terminal sequence: | Corresponds to reference standard:PASS |
Description: | Etanercept (Enbrel) is a tumor necrosis factor (TNF) inhibitor used for treating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. |
Target: | TNF[1] |
References: | [1]. Burness CB, et al. Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases. BioDrugs. 2016 Aug;30(4):371-8. |